Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-25
2005-10-25
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S866000, C548S221000
Reexamination Certificate
active
06958355
ABSTRACT:
The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
REFERENCES:
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4340605 (1982-07-01), Kawamatsu et al.
patent: 4376777 (1983-03-01), Kawamatsu et al.
patent: 4438141 (1984-03-01), Kawamatsu et al.
patent: 4444779 (1984-04-01), Kawamatsu et al.
patent: 4461902 (1984-07-01), Kawamatsu et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4687777 (1987-08-01), Meguro et al.
patent: 4703052 (1987-10-01), Eggler et al.
patent: 4725610 (1988-02-01), Meguro et al.
patent: 4873255 (1989-10-01), Yoshioka et al.
patent: 4897393 (1990-01-01), Iijima et al.
patent: 4897405 (1990-01-01), Alessi et al.
patent: 4918091 (1990-04-01), Cantello et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 5002953 (1991-03-01), Hindley
patent: 5061717 (1991-10-01), Clark et al.
patent: 5120754 (1992-06-01), Clark et al.
patent: 5132317 (1992-07-01), Cantello et al.
patent: 5194443 (1993-03-01), Hindley
patent: 5223522 (1993-06-01), Clark et al.
patent: 5232925 (1993-08-01), Hindley
patent: 5260445 (1993-11-01), Hindley
patent: 5266582 (1993-11-01), De Nanteuil et al.
patent: 5480896 (1996-01-01), Malamas et al.
patent: 5677330 (1997-10-01), Abraham et al.
patent: 5955616 (1999-09-01), Ohtani et al.
patent: 6037359 (2000-03-01), Shinkai
patent: 6121288 (2000-09-01), Matsui et al.
patent: 0 306 228 (1989-03-01), None
patent: 0 419 035 (1991-03-01), None
patent: 0 528 734 (1993-02-01), None
patent: 0 548 365 (1993-06-01), None
patent: 0 603 419 (1994-08-01), None
patent: 0 684 242 (1995-11-01), None
patent: 0 801 063 (1997-10-01), None
patent: 0 848 004 (1998-08-01), None
patent: 0 818 232 (1999-06-01), None
patent: 0 919 232 (1999-06-01), None
patent: 0 930 299 (1999-07-01), None
patent: 0 953 355 (1999-11-01), None
patent: 0 992 503 (2000-04-01), None
patent: 1 048 659 (2000-11-01), None
patent: 2 154 551 (2001-04-01), None
patent: WO 89/08551 (1989-09-01), None
patent: WO 91/07107 (1991-05-01), None
patent: WO 92/02520 (1992-02-01), None
patent: WO 93/21166 (1993-10-01), None
patent: WO 97 32863 (1997-09-01), None
patent: WO 98/45291 (1998-10-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 01/00566 (2001-01-01), None
patent: WO 01 02377 (2001-01-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16132 (2001-03-01), None
patent: WO 01/81328 (2001-11-01), None
patent: WO 02/24689 (2002-03-01), None
patent: WO 02/44127 (2002-06-01), None
Database Caplus ‘Online! Chemical Abstracts Service,’ Columbus, OH, USA; Database accession No. 128:13261, XP002181181 RN 199167-77-G and 199187-78-8 and JP 09301963 A (Kyorin Pharmaceutical Co., Ltd.) Nov. 25, 1997.
Database Caplus ‘Online! Chemical Abstracts Service,’ Columbus, OH, USA; Database acession No. 127:161819, XP002181182, RN 193544-82-0 and JP 09165371 A (Sankyo Co., Ltd.), Jun. 24, 1997.
Kletzien, R.F., et al., “Enhancement of Adipcyte Differenttation by an Insulin-Sansitizing Agent,”Molecular Pharmacology(Feb. 1, 1992) 41(2):393-8, XP002081233, The American Society for Pharmacology and Experimental Therapeutics.
Sohda, T., et al., “Studies on Antidiabetic Agents, II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its Derivatives,”Chem. Pharm. Bull.(1982) 30(10):3580-3600. XP002042079.
Urangst, P.C., et al., “Synthesis and Biological Evaluation of 5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxy phenyl]methylene]oxazoles, -thiazoles, and -imidazoles: Novel Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors with Antiinflammatory Activity,”J. Med. Chem.(1994) 37(2):322-8, XP002127023, American Chemical Society.
Kinoshita, S. et al., “Preparation of N-benzyl (dioxothiazolidyl)benzamides and Their Use as Oral Antidiabetics and Hypothemic Agents,” Database Caplus 'Online! Chemical Abstracts Service, 1997, Columbus, Ohio, Database accession No. 128:13261, abstract No. XP002181181.
Fujita, T. et al. “Preparation and Formation of Thiazolldinediones as Pharmaceuticals,” Caplus 'Online! Chemical Abstracts Service, 1997, Columbus, Ohio, Database accession No. 127:161819, abstract No. XP002181182.
Crespi, C.L., et al., “Microlitter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450,”Anal. Biochem.(1997) 248:188-190, Pub: Academic Press.
Crespi, C.L., “Higher-throughput screening with human cytochromes P450,”Curr. Op. Drug Discov. Dev.(1999) 2:15-19.
Crespi, C.L., et al., “Novel High throughput fluorescent cytochrome P450 assays,”Toxicol. Sci.48, abstr. No. 323 (1999).
Favreau, L.V., et al., “Improved Reality of the Rapid Microlitter Plate Assay Using Recombinant Enzyme in Predicting CYP2D6 Inhibition in Human Liver Microsomes,”Drug Metab.&Dispos.(1999) 27(4):436-439, Pub: The American Society for Pharmacology & Experimental Therapeutics.
Houston, J.B., “Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance,”Biochem. Pharmacol.(1994) 47(9):1469-79.
Irvine, J.D., et al., “MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening,”J. Pharm. Sci.(1999) 88(1):28-33, Pub: American Chemical Society Society and American Pharmacological Society.
Korzekwa, K.R., et al., “Evaluation of Atypical Cytochrome P450 Kinetics With Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites,”Biochemistry(1998) 37:4137-47.
Kostrubsky, V.E., et al., “Effect of taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: Comparison to dexamethasone,”Toxicol. Appl. Pharmacol.(1997) 142:79-86.
Stewart, B.H., et al., “Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans,”Pharm. Res.(1996) 12:693-99.
Swanson, H.I., “The AH-receptor, genetics, structure and function,”Pharmacogenetics(1993) 3:213-30.
Tiller, P.R., et al., “Immobilized human serum albumin: Liquid chromatography/mass spectrometry as a method of determining drug-protein binding,”Rapid. comm. Mass spectrom.(1995) 9:261-3.
Database CAPLUS ‘Online! Chemical Abstracts Service,’ Columbus, Ohio, USA; Database Accession No. 127:248106, XP002222346, Torii Pharmaceutical Co., Ltd., Japan, 1997.
Database CHEMCATS, AsInEx Compound Collection, Moscow, Russia; Accession No. 2001:694380, May 10, 2001; XP002222347.
Database CHEMCATS, Pharma Library Collection, Nanosyn Combinational Synthesis, Inc., Mountain View, CA, USA; Accession No. 2001:54111, May 14, 2001; XP002222348.
Database CHEMCATS, Ambinter Exploratory Library, Paris, France; Accession No. 2002:1116502, Jan. 21, 2002; XP002222349.
Cantello, B., et al., “[[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolinediones as Potent Antihyperglycemic Agents,”J. Med. Chem.(1994), 37:3977-3985; XP-001094112; American Chemical Society.
Chen, L., et al., “Focused Library Appraoch for Identification of N-Acylphenylalanines as VCAM/VLA-4 Antagonists”,Bioorg. Med. Chem. Lett.(2002), 12:1679-1682; XP-002230539; Elsevier Science Ltd.
Database Crossfire Beilstein; Beilstein Registry No.: 6526484; Beilstein Institut zur Foerderung der Chemischen Wissenschaften; XP-002230540; Frankfurt am Main, DE, 1994.
Haigh,
Druzgala Pascal
Milner Peter G.
Pfister Jurg R.
ARYx Therapeutics, Inc.
Badio Barbara P.
McDonnell Boehnen & Hulbert & Berghoff LLP
LandOfFree
Materials and methods for the treatment of diabetes,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for the treatment of diabetes,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for the treatment of diabetes,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435869